Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Operating Expenses (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Operating Expenses for 7 consecutive years, with $23.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 55.78% to $23.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $156.4 million through Dec 2025, down 31.52% year-over-year, with the annual reading at $156.4 million for FY2025, 31.52% down from the prior year.
  • Operating Expenses for Q4 2025 was $23.6 million at Pliant Therapeutics, down from $28.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $62.0 million in Q3 2024, with the low at $23.6 million in Q4 2025.
  • Average Operating Expenses over 5 years is $40.6 million, with a median of $41.4 million recorded in 2022.
  • The sharpest move saw Operating Expenses soared 48.0% in 2022, then crashed 55.78% in 2025.
  • Over 5 years, Operating Expenses stood at $26.6 million in 2021, then soared by 48.0% to $39.4 million in 2022, then increased by 19.49% to $47.0 million in 2023, then increased by 13.36% to $53.3 million in 2024, then plummeted by 55.78% to $23.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $23.6 million, $28.3 million, and $45.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.